GLG News by Cardiac Electrophysiologists (US)

Daniel Weiss, President

Daniel WeissPresidentWeiss Consulting Groups, Inc. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Medtronic - the new Guidant?

October 18, 2007

Medtronic Pulls Heart Device Wires | www.thestreet.com

The current recall is yet another in the world of cardiac rhythm devices. The ICD market is already shakey and may be adversely affected. Will Medtronic's reputation suffer?

Daniel Weiss, President

Daniel WeissPresidentWeiss Consulting Groups, Inc. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement

September 17, 2007

ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com

TB-402 is a new anticoagulant candidate that seeks to fill a desperate unmet need in a variety of different medical conditions. It would be easily administered with a low risk of patient noncompliance, have reversible effects, and potentially safer than currently available alternatives.

Hossein Ardehali, Associate Professor

Hossein ArdehaliAssociate ProfessorNorthwestern University, Feinberg School of Medicine What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New studies suggest DES may improve outcome in the setting of AMI

September 19, 2006

NEJM Articles on DES in MI | content.nejm.org

The studies reported in the recent issues of NEJM are significant in that they provide evidence that DES in the setting of AMI with ST elevation may improve outcome. Taxel-eluting stents showed nonsignificant improvement in adverse cardiac events, but sirolimus-eluting stents showed a significant reduction in target vessel revascularization

 

Hossein Ardehali, Associate Professor

Hossein ArdehaliAssociate ProfessorNorthwestern University, Feinberg School of Medicine What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Generic clopidogrel should not alter its use

August 18, 2006

Mixed thoughts on how generic clopidogrel might impact patients, providers | www.theheart.org

There are clear indications to use clopidogrel

Clopidogrel should not be used in every patient with coronary artery disease

Page : 11 to 4 of 4

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News